Next Article in Journal
RNA Profile of Cell Bodies and Exosomes Released by Tumorigenic and Non-Tumorigenic Thyroid Cells
Previous Article in Journal
HR-MAS NMR Metabolomics Profile of Vero Cells under the Influence of Virus Infection and nsP2 Inhibitor: A Chikungunya Case Study
Previous Article in Special Issue
Beneficial Effects of O-GlcNAc Stimulation in a Young Rat Model of Sepsis: Beyond Modulation of Gene Expression
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 3
10.3390/ijms25031417
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia

by
Julien M. P. Grenier
1,2,
Wassim El Nemer
1,2 and
Maria De Grandis
1,2,*
1
Etablissement Français du Sang PACA-Corse, Aix Marseille University, CNRS, ADES UMR 7268, 13005 Marseille, France
2
Laboratoire d’Excellence GR-Ex, 75015 Paris, France
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(3), 1417; https://doi.org/10.3390/ijms25031417
Submission received: 23 December 2023 / Revised: 18 January 2024 / Accepted: 22 January 2024 / Published: 24 January 2024
(This article belongs to the Collection State-of-the-Art Molecular Mechanisms of Hematopathology in France)
Browse Figures
Versions Notes

Abstract

:
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) characterized by clonal erythrocytosis and thrombocytosis, respectively. The main goal of therapy in PV and ET is to prevent thrombohemorrhagic complications. Despite a debated notion that red blood cells (RBCs) play a passive and minor role in thrombosis, there has been increasing evidence over the past decades that RBCs may play a biological and clinical role in PV and ET pathophysiology. This review summarizes the main mechanisms that suggest the involvement of PV and ET RBCs in thrombosis, including quantitative and qualitative RBC abnormalities reported in these pathologies. Among these abnormalities, we discuss increased RBC counts and hematocrit, that modulate blood rheology by increasing viscosity, as well as qualitative changes, such as deformability, aggregation, expression of adhesion proteins and phosphatidylserine and release of extracellular microvesicles. While the direct relationship between a high red cell count and thrombosis is well-known, the intrinsic defects of RBCs from PV and ET patients are new contributors that need to be investigated in depth in order to elucidate their role and pave the way for new therapeutical strategies.

1. Introduction

Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are a group of blood disorders characterized by clonal expansion of abnormal hematopoietic stem/progenitor cells resulting in an overabundance of erythrocytes, white blood cells (WBCs) and platelets. The two most common MPNs are polycythemia vera (PV), in which patients present increased red cell mass, often associated with increased platelet and white cell counts, and essential thrombocythemia (ET), which is defined by an elevated platelet count but normal red cell mass [1]. The dysregulation of the JAK/STAT pathway is the mechanistic hallmark of MPNs and is caused by somatic mutations in driver genes including JAK2, CALR and MPL. In 95% of patients with PV and 60% of those with ET, a single somatically acquired mutation is found in the gene encoding JAK2 [2,3,4,5], resulting in the V617F substitution at the protein level that dysregulates the kinase activity and drives the ligand-independent activation of receptor signaling. In JAK2V617F-negative PV cases, somatic gain-of-function mutations were found in JAK2 exon 12 conferring EPO-independent autonomous growth and EPO-hypersensitivity to bone marrow colonies, both in vitro and in vivo [6]. Compared to the V617F mutation, the exon 12 mutation results in stronger ligand-independent signaling and patients are characterized by higher hemoglobin levels and isolated erythrocytosis [7].
The major causes of morbidity and mortality in PV and ET are arterial and venous complications, progression to myelofibrosis and transformation to acute leukemia.
The pathogenesis of thrombosis results from a complex interplay of clinical and disease-related factors. Abnormalities of blood cells arising from the clonal proliferation of mutated hematopoietic stem cells involve not only quantitative changes but also qualitative modifications that characterize the switch of these cells from a resting to a procoagulant phenotype. Several studies indicate that vascular risk is substantially increased in PV and ET patients, even in relatively young patients with no previous vascular history, and becomes very high in older patients with a prior vascular event. The incidence range of arterial and venous thrombosis is 12–39% in PV and 11–25% in ET [8], with continuous efforts to disclose the underlying mechanisms. In many instances, thrombosis first occurs at the time of diagnosis, but cardiovascular events continue to occur during follow-up, even in treated patients. Thromboses are both arterial and venous and may occur virtually in any area. Arterial thrombosis, including acute myocardial infarction, cerebrovascular ischemic episodes and peripheral arterial occlusion, represent 60 to 70% of all cardiovascular events in PV. PV patients also experience deep vein thrombosis and pulmonary embolism. Moreover, they show a high prevalence of rare forms of thrombosis, such as abdominal vein thrombosis, including extrahepatic portal vein occlusion, Budd–Chiari syndrome and mesenteric vein thrombosis [9].
Risk stratification in PV and ET has been designed to estimate the likelihood of thrombotic complications [10]. Predictors of arterial complications include age > 60 years, leukocytosis >11 G/L, prior history of thrombosis, and cardiovascular risk factors [11]. High-risk PV and ET patients require cytoreductive therapy, while low-risk patients require daily aspirin therapy [10]. The first-line drug of choice for cytoreductive therapy, in both PV and ET, is hydroxycarbamide (HC), while the second-line drugs of choice include pegylated-interferon alpha (IFN) [10].
The pathophysiology of thrombosis in PV and ET is multifactorial and complex, a variety of blood cells have been reported to participate in this mechanism. In PV, platelets and leukocytes show a number of morphological, functional and biochemical abnormalities. PV platelets have increased surface expression of P-selectin, thrombospondin and activated fibrinogen receptor GPIIb/IIIa [12,13]. Moreover, they show an abnormal activation associated with modified cell surface localization and the stability of the cMPL receptor [14]. As a matter of fact, it has been shown that JAK2 mutations impair cMPL signal transduction for TPO-induced platelet priming leading to chronic platelet hyperresponsiveness [15]. Increased WBC count is associated with vascular risk in PV and ET patients [16]. In addition to the cell count, abnormal leukocyte activation is found in these patients. Activated leukocytes release an array of substances as reactive oxygen species (ROS) and proteolytic enzymes contributing to the activation of the hemostatic system, the inactivation of physiological inhibitors of coagulation and the formation of neutrophil/platelet complexes [17]. Platelet and leukocyte activation perturb the resting state of the endothelium and turns it into a prothrombotic surface. This damage triggers the release of Von Willebrand factor (vWF) in the circulation which in turn binds to platelets and activates their aggregation and the subsequent reinforcement of the clot in an amplification loop [18]. The presence of the JAK2V617F mutation was reported in endothelial cells (ECs) [19], with in vivo and in vitro studies showing the pro-thrombotic nature of the cells bearing the mutation [20,21]. In these studies, mice with endothelial-specific JAK2V617F expression displayed a higher propensity for thrombus formation due to the pro-adhesive phenotype of mutated ECs, associated with the increased expression levels of vWF and P-selectin (CD62P) [20,21].
For a long time, red blood cells (RBCs) were considered to be passive contributors to thrombotic events [22]. In recent years, clinical and epidemiological studies have associated quantitative and qualitative abnormalities of RBCs with both arterial and venous thrombosis. A growing body of mechanistic studies suggests that RBCs can promote thrombus formation and enhance thrombus stability. These findings suggest that RBCs may contribute to the pathophysiology of thrombosis, paving the way to potential therapeutical strategies targeting RBCs to prevent thrombosis or reduce its incidence [23]. In the context of MPNs, several RBC-related abnormalities have been reported, such as increased RBC count, altered RBC deformability, abnormal expression and activation of adhesion proteins, and release of extracellular microvesicles. These abnormalities contribute to increased vascular resistance and enhanced interaction of RBCs with the vascular wall, which may contribute to thrombus formation. In this review, we summarize the main findings of the literature that suggest an active role for RBCs in PV and ET thrombotic complications.

2. Quantitative and Qualitative Features of PV and ET RBCs in Relation to Thrombosis

RBCs are the most abundant cell type in the body. Their primary role is to transport oxygen to the tissues and carbon dioxide to the lungs. With their flexible structure, RBCs are capable of deforming in order to travel through all blood vessels including very small capillaries. Throughout the 120 days of their lifespan in circulation, RBCs travel in the bloodstream and come in direct or indirect contact with almost all of the cell types of the organism. For a long time, RBCs were considered to be passive carriers of respiratory gases; however, emerging evidence highlights a more complex physiological role. This was brought by recent discoveries demonstrating altered RBC functions in the context of hematological and non-hematological disorders.

2.1. Elevated Hematocrit and Rheological Parameters

Being the major cellular component of blood, RBCs play a central role in defining and regulating the rheological parameters of the bloodstream. Hematocrit (HCT) represents the ratio of the volume of RBCs to the total volume of the blood [24]. Walton et al. showed that mice with high HCT, irrespective of platelet count and thrombin generation, had a reduced bleeding time after injury and a faster artery occlusion arising from accelerated platelet accumulation in the vicinity of the clot [25]. One of the major criteria in PV diagnosis is the presence of elevated HCT resulting from excessive erythrocytosis. The prothrombotic role of elevated HCT has been clearly demonstrated in PV [26,27], as patients maintaining an HCT target of less than 45% showed a lower rate of thrombotic complications as compared to those with a target of 45 to 50% [28]. Moreover, using a PV mouse model, it was shown that stalled blood flow in brain capillaries was correlated with high HCT [29]. Elevated HCT contributes to thrombotic complications by increasing blood viscosity, reducing blood return through the venous system and increasing platelet adhesion. Increased blood viscosity promotes blood clot formation and increases platelet activation at the vessel wall. Under low shear rates, as in the venous bed, hyperviscosity causes a major disturbance to the blood flow and at high shear rates, as in the arteries, the increase in the red cell mass displaces platelets toward the vessel wall, thus facilitating shear-induced platelet activation and enhancing platelet–platelet interactions. The pathogenesis of a thrombus is multifactorial, and it is admitted that its occurrence is mainly determined by the interrelation of the three physiological factors of Virchow’s triad: the hypercoagulability of the blood, the stasis of blood flow and the intravascular damage of the vessel wall. Erythrocytosis has a negative effect on all components of Virchow’s triad (Figure 1). The elevated RBC count in PV is responsible for increased viscosity, slowing down the blood flow, acting as a strong prothrombotic factor. All together, these observations suggest that preserving a normal hematocrit in these patients might further diminish the occurrence of serious thrombotic complications. However, thrombotic events could be still observed in some patients under cytoreductive treatment [30] suggesting that besides hematocrit, other parameters contribute to thrombosis physiopathology in PV.

2.2. Altered Deformability

The rheological properties of RBCs play an important role in their microcirculation. Deformability is an essential feature of RBCs that enables them to circulate through the smallest capillaries of the human body. Physiologically, RBCs, that have a 7–8 μm diameter, change their native biconcave shape to a bullet-like shape every time they squeeze through 1–3 μm blood vessels. This deformation is critical to ensure a high interface area with the vessel wall that is necessary for the efficient exchange of oxygen and carbon dioxide between the blood and tissues. Deformability is a function of (i) the structural proteins of the cytoskeleton, (ii) processes controlling intracellular ion and water handling and (iii) the membrane surface-to-volume ratio.
The deformability of RBCs is critical for the blood flow, even a slight decrease in RBC deformability may cause a significant increase in microvascular flow resistance and blood viscosity, which may lead to thrombotic complications. Investigations of PV RBC morphodynamics using laser-assisted approaches have shown a significant reduction in PV RBC deformability [31]. Dąbrowski and colleagues showed an elevated activity of glucose-6-phosphate dehydrogenase and acetylcholinesterase in PV RBCs that together with elevated levels of glutathione and malonyldialdehyde can explain their increased rigidity [32] (Figure 2). Ektacytometry experiments using LoRRca (laser-optical rotational red cell analyzer), confirmed the reduced deformability and elasticity of PV RBCs and showed increased aggregation amplitude compared to those from heathy donors [31]. Interestingly, this increased aggregation discriminates patients with a high risk of stroke among PV patients [33].
Intracellular Ca2+ is a potent effector of RBC biophysical and rheological properties that may play a role in thrombus formation [34]. Several studies have shown that calcium homeostasis may be altered in PV RBCs, with (i) higher levels of free intracellular Ca2+ as compared to healthy RBCs [35], (ii) elevated levels of Ca2+-binding proteins, such as calnexin and calreticulin and (iii) reduced levels of ATPase plasma membrane Ca2+ transporting 4 (PMCA4B), responsible for Ca2+ export [36]. Increased free intracellular Ca2+ levels in PV RBCs may lead to increased Gárdos channel activity, promoting potassium efflux and subsequent cell dehydration and rigidification (Figure 2). Intracellular Ca2+ accumulation in PV RBCs seems to be associated with the presence of JAK2V617F, which attributes a role for this mutation in the alteration of RBC biochemical and biomechanical properties, that in turn may contribute to thrombosis.

2.3. Enhanced RBC Adhesion to the Vascular Endothelium

In physiological conditions, interactions and adhesion events between circulating RBCs, endothelial cells and other circulating cells are minimal. In some pathological conditions, RBCs were reported to be sticky and to activate the cells of the vascular bed resulting in vaso-occlusion, as observed in sickle-cell disease [37,38,39,40]. Unexpectedly for a circulating non-adhesive cell, the RBC expresses a panel of adhesion molecules at its surface. These proteins play an important role in normal red cell development and some of them contribute to clinical complications in pathophysiology. Selectin receptors expressed on RBCs actively participate in leukocytes “rolling” on endothelial cells whereas intercellular adhesion molecule 4 (ICAM-4), CD44, and Lutheran/basal cell adhesion molecule (Lu/BCAM) are involved in firm interactions. It was shown that sickle RBCs could bind to the subendothelial matrix exposed after endothelial damage, partly through an interaction involving Lu/BCAM [41,42]. Of note, the phosphorylation of serine 621 in the cytoplasmic tail of Lu/BCAM is responsible for the activation of Lu-mediated cell adhesion to laminin 511/521 [43]. Wautier et al. showed increased adhesion of RBCs from PV patients to endothelial cells under static and flow conditions [44] (Figure 2). This increased adhesion was mediated by erythroid Lu/BCAM and endothelial laminin 511/521. Moreover, they showed that in PV RBCs Lu/BCAM was overexpressed and constitutively phosphorylated through a JAK2V617F/Rap1/Akt-signaling pathway targeting serine 621 [45] (Figure 2). In vivo, the shear stress in the postcapillary venules varies from 0.1 to 0.5 Pa; the adhesion of PV RBCs is established in this range and a proportion of adherent cells could withstand such forces suggesting the existence of a high-affinity adhesive interaction. In addition to Lu/BCAM, PV RBCs show the abnormal expression of several proteins, including proteins from the endoplasmic reticulum, such as calreticulin and calnexin, and transporters, like ATP binding cassette Subfamily G member 2 (ABCG2) [36], that could directly or indirectly affect cell surface properties. Moreover, elevated values of malonyldialdehyde associated with lipid peroxidation and reactive oxygen species (ROS) production were described in PV RBCs [32] (Figure 2). Such high values in a PV context may promote RBC adhesion to endothelial cells as ROS production is known to increase the expression of cell adhesion molecules intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) on the vascular endothelium through NF-kB activation [46] (Figure 2). Pegylated-interferon alpha (IFN) and hydroxycarbamide (HC) are commonly used to treat PV and ET. HC efficacy in preventing thrombosis was suggested in several randomized clinical trials but is still not proven [28]. HC but not IFN enhances the expression of several proteins in PV red cell ghosts, including Lu/BCAM and CD147 adhesion proteins, and further exacerbates RBC adhesion to laminin in vitro [47].

2.4. Phosphatidylserine Exposure

Phosphatidylserine (PS) is an amino-phospholipid known to play a crucial role in mediating the recognition of senescent RBCs, serving as an eat-me signal. During aging, upon injury of cells or under certain pathological conditions, scramblase translocates PS from the inner to the outer leaflet, leading to increased concentrations on the external surface [48]. Peyrou et al. suggested that these PS-expressing RBCs may be a source of thrombin generation through the meizothrombin pathway and may play an active role in clot formation and stabilization [49] (Figure 2). PS-expressing RBCs could also contribute to thrombus formation via platelet activation. In anemic mice, a small population of RBCs was located in platelet thrombi and RBC/platelet interaction via FasL/FasR induced externalization of PS on the RBC membrane and enhanced platelet activation were observed [50].
PV patients are characterized by increased PS exposing RBCs/platelets, which could contribute to their hypercoagulable state [51]. While ~0.5–0.6% of the RBC population normally express PS in healthy subjects, the contribution of RBCs in pathological conditions may reach 40% of the thrombin-generating potential of whole blood [52]. Several studies using static adhesion assays or flow-based adhesion models have indicated that PS could participate to RBC adherence to endothelium [53,54,55]: RBCs can directly bind to CD36 and PS-receptor (PSR) on ECs [56] as well as to Chemokine (C-X-C motif) ligand 16 (CXCL16) or CD36 present on activated platelets [57] (Figure 2). The levels of PS-exposing RBCs are also higher in ET patients compared to healthy donors, with the highest levels observed in ET patients harboring JAK2 mutations. PS exposing RBCs were shown to contribute to the hypercoagulable state in ET patients by increasing the production of Factor Xa (FXa), thrombin and fibrin [58] (Figure 2).

2.5. RBC-Derived Microvesicles

Microvesicles (MVs) derived from RBCs are membranous extracellular structures shed into plasma with a diameter of 50–200 nm. They play an important role as key mediators of intercellular communication and consequently have an impact on various physiological processes such as blood homeostasis [59]. RBC-derived MVs expose on their surface antigens derived from the RBC membrane such as Glycophorin A (GPA) and Band 3, as well as PS (Figure 2). It was shown that RBC-derived MVs accumulate during blood storage and might be responsible for an increased incidence of deep vein thrombosis or other thrombotic conditions after transfusion of blood units that have been stored for a long duration [60]. Moreover, higher levels of MVs are associated with a dose- and time-dependent increase of thrombin generation and a reduction in clotting time, suggesting that they enhance hypercoagulability [61]. This enhanced thrombin generation has been associated with the expression of PS [62]. Alternatively, RBC-derived MVs can initiate thrombin formation either via a factor XII-dependent pathway or via the direct activation of FIX in a kallikrein-dependent manner [63] without tissue factor activity [64] (Figure 2). The circulating MVs can also promote vaso-occlusion by internalizing free heme and transferring it to the vascular endothelium or activating the complement system [65].
MPN patients have higher plasmatic levels of MVs than healthy individuals, with the MVs being derived from RBCs, platelets and endothelial cells. MV levels were shown to be higher in MPN patients having experienced thrombotic events [66,67]. In addition to this quantitative parameter related to their concentration in the circulation, MVs show a membrane and content composition that is specific to PV patients. As a matter of fact, JAK2V617F RBC-derived MVs were shown to be responsible for increased endothelial oxidative stress and nitric oxide (NO) pathway inhibition, increasing arterial contraction that accounts for the arterial events associated with the disease. At the molecular level, PV RBC-derived MVs have a defect in glutathione S-transferase theta 1 (GSTT1) and an overexpression of myeloperoxidase (MPO) [68] (Figure 2). MPO disrupts vascular endothelium by destabilizing the glycocalyx, resulting in neutrophil recruitment and the generation of neutrophil extracellular traps (NETs) [69]. NETs are directly involved in thrombus generation via various mechanisms that have been reviewed elsewhere [70]. A various number of clinical studies have shown that serum MPO and DNA levels are associated with an increased risk of deep vein thrombosis and pulmonary embolism in humans [71,72,73,74] suggesting that MPO levels might be used as a biomarker in patients with PV and ET.
A recent paper associates increased levels of RBC-derived MVs with pro-thrombotic microenvironment in patients with type 2 diabetes mellitus and suggests monitoring RBC-derived MVs levels by flow-cytometry as a biomarker of thrombotic risk [75]; the possibility needs to be further investigated in PVs and ETs.

2.6. Clinical Relevance of RBC Properties in Thrombotic Risk

In MPNs, thrombotic risk correlates with age, prior thrombosis, hypertension, hyperlipidemia, leukocytosis, JAK2V617F allele burden and therapy in some, but not all, studies, but only age and prior thrombosis are included in thrombosis risk stratification. Recently, several studies reported that RBC distribution width (RDW) predicts thrombosis in patients with PV [76,77,78,79]. RDW is a parameter that measures the size and the volume of RBCs, but the relation between RDW values and thrombotic events remains unclear. However, it has been demonstrated that higher RDW values are associated with decreased RBC deformability [80] leading to erythrocytes aggregation, increased blood viscosity and thrombotic susceptibility [81,82].

3. Conclusions and Perspectives

The ability of RBCs to promote thrombosis is multifactorial, with several underlying mechanisms that are probably needed in concert. Although RBCs are not known to be the drivers of thrombotic events, the studies cited in this review are important elements supporting the active role of RBCs in this pathological manifestation in PV and ET. While the direct relationship between a high red cell count and thrombosis is well-known, the intrinsic defects of RBCs from PV and ET patients are new contributors that need to be investigated in depth in order to elucidate their role and pave the way for new biomarkers (Table 1) and therapeutical strategies.

Author Contributions

J.M.P.G., W.E.N. and M.D.G. wrote and edited the manuscript. J.M.P.G. designed and crafted the figures using Biorender. All authors have read and agreed to the published version of the manuscript.

Funding

The work was supported by Etablissement Français du Sang (EFS), Aix-Marseille University (AMU), Centre National de la Recherche Scientifique (CNRS), and grants from the French National Research Agency, the IRIS project reference No. ANR-21-CE14-0063, and from the Laboratory of Excellence (Labex) GR-Ex, reference No. ANR-11-LABX-0051. The Labex GR-Ex is funded by the IdEx program “Investissements d’avenir” of the French National Research Agency, reference No. ANR-11-IDEX-0005-02 and ANR-18-IDEX-0001.

Institutional Review Board Statement

Not applicable.

Acknowledgments

In memory of Marie-Paule Wautier, who introduced us to the field of myeloproliferative neoplasms and accompanied us during several years of investigation.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016, 127, 2391–2405. [Google Scholar] [CrossRef] [PubMed]
  2. Baxter, E.J.; Scott, L.M.; Campbell, P.J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G.S.; Bench, A.J.; Boyd, E.M.; Curtin, N.; et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365, 1054–1061. [Google Scholar] [CrossRef] [PubMed]
  3. James, C.; Ugo, V.; Le Couedic, J.P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garcon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434, 1144–1148. [Google Scholar] [CrossRef] [PubMed]
  4. Kralovics, R.; Passamonti, F.; Buser, A.S.; Teo, S.S.; Tiedt, R.; Passweg, J.R.; Tichelli, A.; Cazzola, M.; Skoda, R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352, 1779–1790. [Google Scholar] [CrossRef] [PubMed]
  5. Levine, R.L.; Wadleigh, M.; Cools, J.; Ebert, B.L.; Wernig, G.; Huntly, B.J.; Boggon, T.J.; Wlodarska, I.; Clark, J.J.; Moore, S.; et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7, 387–397. [Google Scholar] [CrossRef] [PubMed]
  6. Scott, L.M.; Tong, W.; Levine, R.L.; Scott, M.A.; Beer, P.A.; Stratton, M.R.; Futreal, P.A.; Erber, W.N.; McMullin, M.F.; Harrison, C.N.; et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 2007, 356, 459–468. [Google Scholar] [CrossRef]
  7. Passamonti, F.; Elena, C.; Schnittger, S.; Skoda, R.C.; Green, A.R.; Girodon, F.; Kiladjian, J.J.; McMullin, M.F.; Ruggeri, M.; Besses, C.; et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011, 117, 2813–2816. [Google Scholar] [CrossRef]
  8. Elliott, M.A. Chronic neutrophilic leukemia: A contemporary review. Curr. Hematol. Rep. 2004, 3, 210–217. [Google Scholar]
  9. Marchioli, R.; Finazzi, G.; Landolfi, R.; Kutti, J.; Gisslinger, H.; Patrono, C.; Marilus, R.; Villegas, A.; Tognoni, G.; Barbui, T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J. Clin. Oncol. 2005, 23, 2224–2232. [Google Scholar] [CrossRef]
  10. Tefferi, A.; Barbui, T. New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera. Am. J. Hematol. 2015, 90, 683–685. [Google Scholar] [CrossRef]
  11. Carobbio, A.; Thiele, J.; Passamonti, F.; Rumi, E.; Ruggeri, M.; Rodeghiero, F.; Randi, M.L.; Bertozzi, I.; Vannucchi, A.M.; Antonioli, E.; et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients. Blood 2011, 117, 5857–5859. [Google Scholar] [CrossRef] [PubMed]
  12. Griesshammer, M.; Bangerter, M.; Sauer, T.; Wennauer, R.; Bergmann, L.; Heimpel, H. Aetiology and clinical significance of thrombocytosis: Analysis of 732 patients with an elevated platelet count. J. Intern. Med. 1999, 245, 295–300. [Google Scholar] [CrossRef] [PubMed]
  13. Jensen, M.K.; de Nully Brown, P.; Lund, B.V.; Nielsen, O.J.; Hasselbalch, H.C. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br. J. Haematol. 2000, 110, 116–124. [Google Scholar] [CrossRef] [PubMed]
  14. Royer, Y.; Staerk, J.; Costuleanu, M.; Courtoy, P.J.; Constantinescu, S.N. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J. Biol. Chem. 2005, 280, 27251–27261. [Google Scholar] [CrossRef] [PubMed]
  15. Kubota, Y.; Tanaka, T.; Ohnishi, H.; Kitanaka, A.; Okutani, Y.; Taminato, T.; Ishida, T.; Kamano, H. Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation. Leukemia 2004, 18, 1127–1137. [Google Scholar] [CrossRef] [PubMed]
  16. Landolfi, R.; Di Gennaro, L.; Barbui, T.; De Stefano, V.; Finazzi, G.; Marfisi, R.; Tognoni, G.; Marchioli, R.; European Collaboration on Low-Dose Aspirin in Polycythemia Vera. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007, 109, 2446–2452. [Google Scholar] [CrossRef] [PubMed]
  17. Maugeri, N.; Brambilla, M.; Camera, M.; Carbone, A.; Tremoli, E.; Donati, M.B.; de Gaetano, G.; Cerletti, C. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J. Thromb. Haemost. 2006, 4, 1323–1330. [Google Scholar] [CrossRef] [PubMed]
  18. Falanga, A.; Marchetti, M.; Evangelista, V.; Vignoli, A.; Licini, M.; Balicco, M.; Manarini, S.; Finazzi, G.; Cerletti, C.; Barbui, T. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000, 96, 4261–4266. [Google Scholar] [CrossRef]
  19. Sozer, S.; Fiel, M.I.; Schiano, T.; Xu, M.; Mascarenhas, J.; Hoffman, R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009, 113, 5246–5249. [Google Scholar] [CrossRef]
  20. Guadall, A.; Lesteven, E.; Letort, G.; Awan Toor, S.; Delord, M.; Pognant, D.; Brusson, M.; Verger, E.; Maslah, N.; Giraudier, S.; et al. Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features. Thromb. Haemost. 2018, 118, 1586–1599. [Google Scholar] [CrossRef]
  21. Guy, A.; Gourdou-Latyszenok, V.; Le Lay, N.; Peghaire, C.; Kilani, B.; Dias, J.V.; Duplaa, C.; Renault, M.A.; Denis, C.; Villeval, J.L.; et al. Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica 2019, 104, 70–81. [Google Scholar] [CrossRef] [PubMed]
  22. Byrnes, J.R.; Wolberg, A.S. Red blood cells in thrombosis. Blood 2017, 130, 1795–1799. [Google Scholar] [CrossRef] [PubMed]
  23. Weisel, J.W.; Litvinov, R.I. Red blood cells: The forgotten player in hemostasis and thrombosis. J. Thromb. Haemost. 2019, 17, 271–282. [Google Scholar] [CrossRef] [PubMed]
  24. Wells, R.E., Jr.; Merrill, E.W. Influence of flow properties of blood upon viscosity-hematocrit relationships. J. Clin. Investig. 1962, 41, 1591–1598. [Google Scholar] [CrossRef] [PubMed]
  25. Walton, B.L.; Lehmann, M.; Skorczewski, T.; Holle, L.A.; Beckman, J.D.; Cribb, J.A.; Mooberry, M.J.; Wufsus, A.R.; Cooley, B.C.; Homeister, J.W.; et al. Elevated hematocrit enhances platelet accumulation following vascular injury. Blood 2017, 129, 2537–2546. [Google Scholar] [CrossRef] [PubMed]
  26. Adams, B.D.; Baker, R.; Lopez, J.A.; Spencer, S. Myeloproliferative disorders and the hyperviscosity syndrome. Hematol. Oncol. Clin. N. Am. 2010, 24, 585–602. [Google Scholar] [CrossRef] [PubMed]
  27. Pearson, T.C.; Wetherley-Mein, G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978, 2, 1219–1222. [Google Scholar] [CrossRef]
  28. Marchioli, R.; Finazzi, G.; Specchia, G.; Cacciola, R.; Cavazzina, R.; Cilloni, D.; De Stefano, V.; Elli, E.; Iurlo, A.; Latagliata, R.; et al. Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl. J. Med. 2013, 368, 22–33. [Google Scholar] [CrossRef]
  29. Santisakultarm, T.P.; Paduano, C.Q.; Stokol, T.; Southard, T.L.; Nishimura, N.; Skoda, R.C.; Olbricht, W.L.; Schafer, A.I.; Silver, R.T.; Schaffer, C.B. Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J. Thromb. Haemost. 2014, 12, 2120–2130. [Google Scholar] [CrossRef]
  30. Crodel, C.C.; Jentsch-Ullrich, K.; Reiser, M.; Jacobasch, L.; Sauer, A.; Tesch, H.; Ulshofer, T.; Wunschel, R.; Palandri, F.; Heidel, F.H. Cytoreductive treatment in real life: A chart review analysis on 1440 patients with polycythemia vera. J. Cancer Res. Clin. Oncol. 2022, 148, 2693–2705. [Google Scholar] [CrossRef]
  31. Lo Presti, R.; Caracciolo, C.; Montana, M.; Barone, R.; Catania, A.; Caimi, G. Erythrocyte deformability evaluated by laser diffractometry in polycythemia vera. Clin. Hemorheol. Microcirc. 2012, 50, 189–192. [Google Scholar] [CrossRef] [PubMed]
  32. Dabrowski, Z.; Dybowicz, A.J.; Marchewka, A.; Teleglow, A.; Skotnicki, A.; Zdunczyk, A.; Aleksander, P.; Filar-Mierzwa, K. Elongation index of erythrocytes, study of activity of chosen erythrocyte enzymes, and the levels of glutathione, malonyldialdehyde in polycythemia vera (PV). Clin. Hemorheol. Microcirc. 2011, 47, 169–176. [Google Scholar] [CrossRef]
  33. Kuznetsova, P.I.; Raskurazhev, A.A.; Shabalina, A.A.; Melikhyan, A.L.; Subortseva, I.N.; Tanashyan, M.M. Red Blood Cell Morphodynamics in Patients with Polycythemia Vera and Stroke. Int. J. Mol. Sci. 2022, 23, 2247. [Google Scholar] [CrossRef] [PubMed]
  34. Bogdanova, A.; Makhro, A.; Wang, J.; Lipp, P.; Kaestner, L. Calcium in red blood cells-a perilous balance. Int. J. Mol. Sci. 2013, 14, 9848–9872. [Google Scholar] [CrossRef] [PubMed]
  35. Buks, R.; Dagher, T.; Rotordam, M.G.; Monedero Alonso, D.; Cochet, S.; Gautier, E.F.; Chafey, P.; Cassinat, B.; Kiladjian, J.J.; Becker, N.; et al. Altered Ca2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis. Cells 2021, 11, 49. [Google Scholar] [CrossRef] [PubMed]
  36. Brusson, M.; Cochet, S.; Leduc, M.; Guillonneau, F.; Mayeux, P.; Peyrard, T.; Chomienne, C.; Le Van Kim, C.; Cassinat, B.; Kiladjian, J.J.; et al. Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2(V617F) mutation. Haematologica 2017, 102, e241–e244. [Google Scholar] [CrossRef] [PubMed]
  37. Hebbel, R.P. Adhesion of sickle red cells to endothelium: Myths and future directions. Transfus. Clin. Biol. 2008, 15, 14–18. [Google Scholar] [CrossRef]
  38. Embury, S.H.; Matsui, N.M.; Ramanujam, S.; Mayadas, T.N.; Noguchi, C.T.; Diwan, B.A.; Mohandas, N.; Cheung, A.T. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood 2004, 104, 3378–3385. [Google Scholar] [CrossRef]
  39. Ballas, S.K. Sickle cell anemia with few painful crises is characterized by decreased red cell deformability and increased number of dense cells. Am. J. Hematol. 1991, 36, 122–130. [Google Scholar] [CrossRef]
  40. Lizarralde-Iragorri, M.A.; Lefevre, S.D.; Cochet, S.; El Hoss, S.; Brousse, V.; Filipe, A.; Dussiot, M.; Azouzi, S.; Le Van Kim, C.; Rodrigues-Lima, F.; et al. Oxidative stress activates red cell adhesion to laminin in sickle cell disease. Haematologica 2021, 106, 2478–2488. [Google Scholar] [CrossRef]
  41. Udani, M.; Zen, Q.; Cottman, M.; Leonard, N.; Jefferson, S.; Daymont, C.; Truskey, G.; Telen, M.J. Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin. J. Clin. Investig. 1998, 101, 2550–2558. [Google Scholar] [CrossRef] [PubMed]
  42. El Nemer, W.; Gane, P.; Colin, Y.; Bony, V.; Rahuel, C.; Galacteros, F.; Cartron, J.P.; Le Van Kim, C. The Lutheran blood group glycoproteins, the erythroid receptors for laminin, are adhesion molecules. J. Biol. Chem. 1998, 273, 16686–16693. [Google Scholar] [CrossRef] [PubMed]
  43. Gauthier, E.; Rahuel, C.; Wautier, M.P.; El Nemer, W.; Gane, P.; Wautier, J.L.; Cartron, J.P.; Colin, Y.; Le Van Kim, C. Protein kinase A-dependent phosphorylation of Lutheran/basal cell adhesion molecule glycoprotein regulates cell adhesion to laminin α5. J. Biol. Chem. 2005, 280, 30055–30062. [Google Scholar] [CrossRef] [PubMed]
  44. Wautier, M.P.; El Nemer, W.; Gane, P.; Rain, J.D.; Cartron, J.P.; Colin, Y.; Le Van Kim, C.; Wautier, J.L. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin α5 chain and Lu/BCAM. Blood 2007, 110, 894–901. [Google Scholar] [CrossRef] [PubMed]
  45. De Grandis, M.; Cambot, M.; Wautier, M.P.; Cassinat, B.; Chomienne, C.; Colin, Y.; Wautier, J.L.; Le Van Kim, C.; El Nemer, W. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood 2013, 121, 658–665. [Google Scholar] [CrossRef] [PubMed]
  46. Kim, S.R.; Bae, Y.H.; Bae, S.K.; Choi, K.S.; Yoon, K.H.; Koo, T.H.; Jang, H.O.; Yun, I.; Kim, K.W.; Kwon, Y.G.; et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-κB activation in endothelial cells. Biochim. Biophys. Acta 2008, 1783, 886–895. [Google Scholar] [CrossRef]
  47. Brusson, M.; De Grandis, M.; Cochet, S.; Bigot, S.; Marin, M.; Leduc, M.; Guillonneau, F.; Mayeux, P.; Peyrard, T.; Chomienne, C.; et al. Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera. Haematologica 2018, 103, 972–981. [Google Scholar] [CrossRef]
  48. Nguyen, D.B.; Wagner-Britz, L.; Maia, S.; Steffen, P.; Wagner, C.; Kaestner, L.; Bernhardt, I. Regulation of phosphatidylserine exposure in red blood cells. Cell Physiol. Biochem. 2011, 28, 847–856. [Google Scholar] [CrossRef]
  49. Peyrou, V.; Lormeau, J.C.; Herault, J.P.; Gaich, C.; Pfliegger, A.M.; Herbert, J.M. Contribution of erythrocytes to thrombin generation in whole blood. Thromb. Haemost. 1999, 81, 400–406. [Google Scholar] [CrossRef]
  50. Klatt, C.; Kruger, I.; Zey, S.; Krott, K.J.; Spelleken, M.; Gowert, N.S.; Oberhuber, A.; Pfaff, L.; Luckstadt, W.; Jurk, K.; et al. Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis. J. Clin. Investig. 2018, 128, 3906–3925. [Google Scholar] [CrossRef]
  51. Tan, X.; Shi, J.; Fu, Y.; Gao, C.; Yang, X.; Li, J.; Wang, W.; Hou, J.; Li, H.; Zhou, J. Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. Thromb. Haemost. 2013, 109, 1025–1032. [Google Scholar] [CrossRef] [PubMed]
  52. Whelihan, M.F.; Zachary, V.; Orfeo, T.; Mann, K.G. Prothrombin activation in blood coagulation: The erythrocyte contribution to thrombin generation. Blood 2012, 120, 3837–3845. [Google Scholar] [CrossRef] [PubMed]
  53. Wali, R.K.; Jaffe, S.; Kumar, D.; Kalra, V.K. Alterations in organization of phospholipids in erythrocytes as factor in adherence to endothelial cells in diabetes mellitus. Diabetes 1988, 37, 104–111. [Google Scholar] [CrossRef] [PubMed]
  54. Schlegel, R.A.; McEvoy, L.; Williamson, P. Membrane phospholipid asymmetry and the adherence of loaded red blood cells. Bibl. Haematol. 1985, 51, 150–156. [Google Scholar] [CrossRef]
  55. Closse, C.; Dachary-Prigent, J.; Boisseau, M.R. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br. J. Haematol. 1999, 107, 300–302. [Google Scholar] [CrossRef]
  56. Setty, B.N.; Kulkarni, S.; Stuart, M.J. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood 2002, 99, 1564–1571. [Google Scholar] [CrossRef] [PubMed]
  57. Walker, B.; Towhid, S.T.; Schmid, E.; Hoffmann, S.M.; Abed, M.; Munzer, P.; Vogel, S.; Neis, F.; Brucker, S.; Gawaz, M.; et al. Dynamic adhesion of eryptotic erythrocytes to immobilized platelets via platelet phosphatidylserine receptors. Am. J. Physiol. Cell Physiol. 2014, 306, C291–C297. [Google Scholar] [CrossRef]
  58. Tong, D.; Yu, M.; Guo, L.; Li, T.; Li, J.; Novakovic, V.A.; Dong, Z.; Tian, Y.; Kou, J.; Bi, Y.; et al. Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients. Ann. Hematol. 2018, 97, 605–616. [Google Scholar] [CrossRef]
  59. Westerman, M.; Porter, J.B. Red blood cell-derived microparticles: An overview. Blood Cells Mol. Dis. 2016, 59, 134–139. [Google Scholar] [CrossRef]
  60. Koch, C.G.; Li, L.; Sessler, D.I.; Figueroa, P.; Hoeltge, G.A.; Mihaljevic, T.; Blackstone, E.H. Duration of red-cell storage and complications after cardiac surgery. N. Engl. J. Med. 2008, 358, 1229–1239. [Google Scholar] [CrossRef]
  61. Kim, Y.; Xia, B.T.; Jung, A.D.; Chang, A.L.; Abplanalp, W.A.; Caldwell, C.C.; Goodman, M.D.; Pritts, T.A. Microparticles from stored red blood cells promote a hypercoagulable state in a murine model of transfusion. Surgery 2018, 163, 423–429. [Google Scholar] [CrossRef] [PubMed]
  62. Morel, O.; Jesel, L.; Freyssinet, J.M.; Toti, F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 15–26. [Google Scholar] [CrossRef] [PubMed]
  63. Noubouossie, D.F.; Henderson, M.W.; Mooberry, M.; Ilich, A.; Ellsworth, P.; Piegore, M.; Skinner, S.C.; Pawlinski, R.; Welsby, I.; Renne, T.; et al. Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood 2020, 135, 755–765. [Google Scholar] [CrossRef] [PubMed]
  64. Van Der Meijden, P.E.; Van Schilfgaarde, M.; Van Oerle, R.; Renne, T.; Ten Cate, H.; Spronk, H.M. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J. Thromb. Haemost. 2012, 10, 1355–1362. [Google Scholar] [CrossRef] [PubMed]
  65. Zecher, D.; Cumpelik, A.; Schifferli, J.A. Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 313–320. [Google Scholar] [CrossRef]
  66. Charpentier, A.; Lebreton, A.; Rauch, A.; Bauters, A.; Trillot, N.; Nibourel, O.; Tintillier, V.; Wemeau, M.; Demory, J.L.; Preudhomme, C.; et al. Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia. Haematologica 2016, 101, e365–e368. [Google Scholar] [CrossRef]
  67. Zhang, W.; Qi, J.; Zhao, S.; Shen, W.; Dai, L.; Han, W.; Huang, M.; Wang, Z.; Ruan, C.; Wu, D.; et al. Clinical significance of circulating microparticles in Ph− myeloproliferative neoplasms. Oncol. Lett. 2017, 14, 2531–2536. [Google Scholar] [CrossRef]
  68. Poisson, J.; Tanguy, M.; Davy, H.; Camara, F.; El Mdawar, M.B.; Kheloufi, M.; Dagher, T.; Devue, C.; Lasselin, J.; Plessier, A.; et al. Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm. J. Clin. Investig. 2020, 130, 2630–2643. [Google Scholar] [CrossRef]
  69. Hartman, C.L.; Ford, D.A. MPO (Myeloperoxidase) Caused Endothelial Dysfunction. Arterioscler. Thromb. Vasc. Biol. 2018, 38, 1676–1677. [Google Scholar] [CrossRef]
  70. Xu, X.; Wu, Y.; Xu, S.; Yin, Y.; Ageno, W.; De Stefano, V.; Zhao, Q.; Qi, X. Clinical significance of neutrophil extracellular traps biomarkers in thrombosis. Thromb. J. 2022, 20, 63. [Google Scholar] [CrossRef]
  71. Sharma, S.; Hofbauer, T.M.; Ondracek, A.S.; Chausheva, S.; Alimohammadi, A.; Artner, T.; Panzenboeck, A.; Rinderer, J.; Shafran, I.; Mangold, A.; et al. Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis. Blood 2021, 137, 1104–1116. [Google Scholar] [CrossRef] [PubMed]
  72. Diaz, J.A.; Fuchs, T.A.; Jackson, T.O.; Kremer Hovinga, J.A.; Lammle, B.; Henke, P.K.; Myers, D.D., Jr.; Wagner, D.D.; Wakefield, T.W.; Michigan Research Venous Group. Plasma DNA is Elevated in Patients with Deep Vein Thrombosis. J. Vasc. Surg. Venous Lymphat. Disord. 2013, 1, 341–348. [Google Scholar] [CrossRef] [PubMed]
  73. Lee, K.H.; Cavanaugh, L.; Leung, H.; Yan, F.; Ahmadi, Z.; Chong, B.H.; Passam, F. Quantification of NETs-associated markers by flow cytometry and serum assays in patients with thrombosis and sepsis. Int. J. Lab. Hematol. 2018, 40, 392–399. [Google Scholar] [CrossRef] [PubMed]
  74. Martos, L.; Oto, J.; Fernandez-Pardo, A.; Plana, E.; Solmoirago, M.J.; Cana, F.; Hervas, D.; Bonanad, S.; Ferrando, F.; Espana, F.; et al. Increase of Neutrophil Activation Markers in Venous Thrombosis-Contribution of Circulating Activated Protein C. Int. J. Mol. Sci. 2020, 21, 5651. [Google Scholar] [CrossRef] [PubMed]
  75. Gkaliagkousi, E.; Nikolaidou, B.; Gavriilaki, E.; Lazaridis, A.; Yiannaki, E.; Anyfanti, P.; Zografou, I.; Markala, D.; Douma, S. Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus. Diabetes Vasc. Dis. Res. 2019, 16, 458–465. [Google Scholar] [CrossRef] [PubMed]
  76. Liu, D.; Li, B.; Xu, Z.; Zhang, P.; Qin, T.; Qu, S.; Pan, L.; Sun, X.; Shi, Z.; Huang, H.; et al. RBC distribution width predicts thrombosis risk in polycythemia vera. Leukemia 2022, 36, 566–568. [Google Scholar] [CrossRef] [PubMed]
  77. De Grandis, M.; Cassinat, B.; Kiladjian, J.J.; Chomienne, C.; El Nemer, W. Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients. Am. J. Hematol. 2015, 90, E137–E138. [Google Scholar] [CrossRef] [PubMed]
  78. Krecak, I.; Krecak, F.; Gveric-Krecak, V. High red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera. Blood Cells Mol. Dis. 2020, 80, 102368. [Google Scholar] [CrossRef]
  79. Verstovsek, S.; Krecak, I.; Heidel, F.H.; De Stefano, V.; Bryan, K.; Zuurman, M.W.; Zaiac, M.; Morelli, M.; Smyth, A.; Redondo, S.; et al. Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project. Biomedicines 2023, 11, 1925. [Google Scholar] [CrossRef]
  80. Patel, K.V.; Mohanty, J.G.; Kanapuru, B.; Hesdorffer, C.; Ershler, W.B.; Rifkind, J.M. Association of the red cell distribution width with red blood cell deformability. Adv. Exp. Med. Biol. 2013, 765, 211–216. [Google Scholar] [CrossRef]
  81. Aarts, P.A.; Banga, J.D.; van Houwelingen, H.C.; Heethaar, R.M.; Sixma, J.J. Increased red blood cell deformability due to isoxsuprine administration decreases platelet adherence in a perfusion chamber: A double-blind cross-over study in patients with intermittent claudication. Blood 1986, 67, 1474–1481. [Google Scholar] [CrossRef] [PubMed]
  82. Litvinov, R.I.; Weisel, J.W. Role of red blood cells in haemostasis and thrombosis. ISBT Sci. Ser. 2017, 12, 176–183. [Google Scholar] [CrossRef] [PubMed]
Ijms 25 01417 g001
Figure 1. Thrombus generation: TF: tissue factor; VWF: Von Willebrand factor.
Figure 1. Thrombus generation: TF: tissue factor; VWF: Von Willebrand factor.
Ijms 25 01417 g001
Ijms 25 01417 g002
Figure 2. Contribution of JAK2 mutant RBCs to thrombus pathogenesis: EC: endothelial cells; PS: phosphatidyl serine; PSR: phosphatidyl serine receptor; MVs: microvesicles.
Figure 2. Contribution of JAK2 mutant RBCs to thrombus pathogenesis: EC: endothelial cells; PS: phosphatidyl serine; PSR: phosphatidyl serine receptor; MVs: microvesicles.
Ijms 25 01417 g002
Table 1. RBC-related biomarkers for prediction of thrombotic events in PV and ET patients.
Table 1. RBC-related biomarkers for prediction of thrombotic events in PV and ET patients.
ParameterRead OutClinical Routine Compatible
HematocritBlood countyes
RBCs deformabilityLoRRcayes
Ca2+ concentrationFluorescence/Ca2+ chelator/
atomic absorption microscopy		difficult
Intracellular proteins Western Blot/FACSno
Adhesion moleculesFACSdifficult
PS exposureFACSyes
RBC derived MVsFACSyes
Serum MPOELISAyes
Oxidative stressqPCR/fluorescencedifficult
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Grenier, J.M.P.; El Nemer, W.; De Grandis, M. Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia. Int. J. Mol. Sci. 2024, 25, 1417. https://doi.org/10.3390/ijms25031417

AMA Style

Grenier JMP, El Nemer W, De Grandis M. Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia. International Journal of Molecular Sciences. 2024; 25(3):1417. https://doi.org/10.3390/ijms25031417

Chicago/Turabian Style

Grenier, Julien M. P., Wassim El Nemer, and Maria De Grandis. 2024. "Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia" International Journal of Molecular Sciences 25, no. 3: 1417. https://doi.org/10.3390/ijms25031417

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop